I've thought about my original question about regular updates and Dr Moro's (quick,k thank you) response. I also glanced at the latest 10Q again.

The bottom line is that I want the company (and especially their technology) to succeed. To do so they will surely need financing...BUT, I have huge concerns about their inability to communicate the master plan, which IMO would reduce the amount of dilution needed by giving the investment community confidence.

Some "followers" here suggest trusting the good doctor, and everything will be fine. Even if I knew the man and could trust the technology, I would not throw money at him unless he explained the game plan. There are lots of bright doctors out there, that are pathetic business managers. To succeed, they hire someone to organize the business side while they focus on their specialty.

I understand the importance of confidentiality in "not yet public" agreements, but there are no timelines or at least prioritized plans identified for any of their endeavours. They are not explained in the 10Q. Further, I think quarterly updates accompanying the 10Q should be posted to the Biocurex website.

Here is a rambling list of claims/facts/questions that I can list off the top of my head. I say them now, because Dr Moro is allegedly at the ISOBM right now, and either he is asleep at the switch or has something up his sleeve. Everything is so nebullous in this company that I could believe either extreme. Hence my concern:

• When posted, the special share issue proposal would generate about 2 million dollars (.07 x 300 mill). Since then the price climbed briefly to almost .30 (which would yield 9 million dollars, and is now sliding back down around .18 as I speak. Company rep said they are looking for 4 to 6 million dollars, but could not say whether the number of shares in a primary offering would be reduced, if stock price was above that necessary (.20?) to generate 6 million.
• There is no "clear" plan to promote the company before said special meeting. Personally, this is where I would be embarking on a dog and pony show to get the stock price up as much as possible, and then reducing the share issuance as much as possible.
• This is not to say that a material change could not occur necessitating a press release before the meeting. For instance, is Dr Moro involved in anything in an official capacity at the symposium? Someone pointed out long ago, that Abbott is doing a session this wednesday entitled (I think) bringing a new biomarker to market. What new biomarker???!!! I doubt it is recaf, unless Abbott is keeping a very tight lid on it. Usually big organizations would be leaking news like a seive and BOCX would be climbing steadily.
• Where the heck is Oncopet in all of this? People on this board sounded like they were quitting their jobs and shopping for yachts back in June. There was lots of discussion, and I personally have spoken to vets who have stated that cancer is currently very difficult to diagnose in dogs. Biocurex rep also said today that response has been huge from vet community. Yet, do a search on ONcopet, and I find very little mention of it since June. I seem to recall one of the company releases talking about "the next few months..." regarding oncopet. A few months have passed and nothing has been mentioned. I don't need to hear who they are dealing with, but are they looking to partner? Do they need 2 million dollars to ramp up? When is revenue anticipated? If they can't answer any of those questions, I have major concerns, as this is supposed to be the short cut to market.
• What about China..."this will require additional, dilutive financing..." a press statement said. Is that higher or lower priority than Abbott et al?

Again, there may be a bunch of hidden good news, but the outside investment community can't be sure of which products/channels/agreements are first in line or what their respective development paths will be.

If ANY of these 4 identified commercialization paths were technically feasible now, a credible company should have no problem generating huge investor interest. If, on the other hand, we are going to hear that they are still years away from commercializing anything, then let me off now. I've watched companies like this go both ways...the vast majority are always a year or two from commercialization. Investors follow a moving target for only so long.

The few that succeed, succeed big.

I am spilling my thoughts, because I think this is the month for management to clarify things. Get the price up over $1 this month, and you would only need to release 6 million shares; not 300 million.